INVO Fertility, Inc (NASDAQ:IVF) Sees Large Decrease in Short Interest

INVO Fertility, Inc (NASDAQ:IVF) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totaling 193,695 shares, a decrease of 47.3% from the August 31st total of 367,548 shares. Approximately 7.8% of the shares of the company are sold short. Based on an average daily volume of 138,917 shares, the short-interest ratio is currently 1.4 days.

INVO Fertility Price Performance

IVF stock traded down $0.01 during trading on Thursday, reaching $0.90. 126,405 shares of the company were exchanged, compared to its average volume of 1,989,174. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.67 and a current ratio of 0.71. The stock’s 50 day moving average price is $1.01 and its 200 day moving average price is $1.60. INVO Fertility has a 52-week low of $0.89 and a 52-week high of $84.40. The company has a market cap of $2.26 million, a P/E ratio of -0.03 and a beta of 2.34.

INVO Fertility (NASDAQ:IVF) last issued its earnings results on Friday, August 14th. The company reported $0.35 earnings per share (EPS) for the quarter. INVO Fertility had a negative net margin of 116.29% and a negative return on equity of 85.54%. The company had revenue of $2.18 million during the quarter.

Analyst Upgrades and Downgrades

IVF has been the topic of several recent analyst reports. Wall Street Zen upgraded INVO Fertility to a “hold” rating in a research report on Saturday, August 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of INVO Fertility in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, INVO Fertility currently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

About INVO Fertility

INVO Fertility, Inc is a medical technology and fertility services company focused on expanding access to in vitro fertilization (IVF) and related assisted reproductive technologies. The company’s primary product is INVOcell, an intravaginal culture system designed to incubate eggs and embryos inside a woman’s body during part of the IVF process, under the supervision of a fertility professional.

INVO Fertility seeks to make fertility treatment more accessible through a combination of medical devices, clinical services, and fertility centers.